Quantitative determination of polymorphic impurity by X-ray powder diffractometry in an OROS® formulation

International Journal of Pharmaceutics

Volumn 366, Issue 1-2, 2009, Pages 74-81

  Varasteh, Mehdi ^a   Deng, Zhengyu ^a   Hwang, Helen ^a   Kim, Yoo Joong ^a   Wong, Geoffrey B ^a  

^a ALZA CORPORATION   (United States)

Author keywords

Drying; Granulation; OROS; Polymorph; Powder X ray diffraction; Quantitation; RWJ 333369

Indexed keywords

CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; MACROGOL;

ARTICLE; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG GRANULATION; DRUG IMPURITY; DRUG MANUFACTURE; DRUG STABILITY; ENANTIOMER; INFRARED SPECTROSCOPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAMAN SPECTROMETRY; SOLID STATE; TABLET COMPRESSION; X RAY POWDER DIFFRACTION;

ANTICONVULSANTS; CARBAMATES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; DRUG STABILITY; DRUG STORAGE; OSMOSIS; TABLETS; TEMPERATURE; THERMODYNAMICS; X-RAY DIFFRACTION;

EID: 57849156178     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.08.049     Document Type: Article

References (15)

1. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids (1999), Marcel Dekker, Inc., New York
2. Bugay D.E., Newman A.W., and Findlay W.P. Quantitation of cefepime.2HCl dihydrate in cefepime. 2HCl monohydrate by diffuse reflectance IR and powder X-ray diffraction techniques. J. Pharm. Biomed. Anal. 15 (1996) 49-61
3. Byrn S., Pfeiffer R., Ganey M., Hoiberg C., and Poochikian G. Pharmaceutical solids: a strategic approach to regulatoriy considerations. Pharm. Res. 12 (1995) 945-954
4. Cao W., Bates S., Peck G., Wldfong, Peter L.D., Qiu Z., and Morris K. Quantitative determination of polymorphic composition in intact compacts by parallel-beam X-ray powder diffractometry. J. Pharm. Biomed. Anal. 30 (2002) 1111-1119
5. Davis T.D., Peck G.E., Stowell J.G., Morris K.R., and Byrn S.R. Modeling and monitoring of polymorphic transformations during the drying phase of wet granulation. Pharm. Res. 21 (2004) 860-866
6. ICH harmonized guideline, 1999. Q6A specifications: test procedures and acceptance criteria for new drug substances and new drug products: chemical substances (including decision trees).
7. ICH harmonized guideline, 2003. Q1A(R2) stability testing of new drug substances and products.
8. Kontoyannis C.G., Orkoula M.G., and Koutsoukos P.G. Quantitative analysis of sulfated calcium carbonates using Raman spectroscopy and X-ray powder diffraction. Analyst 122 (1997) 33-38
9. Nunes C., Mahendrasingam A., and Suryanarayanan R. Quantification of crystallinity in substantially amorphous materials by synchrotron X-ray powder diffractometry. Pharm. Res. 22 (2005) 1942-1953
10. Okumura T., and Otsuka M. A novel standard sample powder preparation method for quantitative analysis of polymorphs. J. Pharm. Sci. 94 (2005) 1013-1023
11. Roberts S.N.C., Williams A., Grimsey I.M., and Booth S.W. Quantitative analysis of mannitol polymorphs. X-ray powder diffractometry-exploring preferred orientation effects. J. Pharm. Biomed. Anal. 28 (2002) 1149-1159
12. Stephenson G.A., Forbes R.A., and Reutzel-Edens S.M. Characterization of the solid state: quantitative issues. Adv. Drug Deliv. Rev. 48 (2001) 67-90
13. Theeuwes, F., Wong, P., Cortese, R., Eckenhoff, J., 1990. ALZA Corp., assignee. Juxtaposed laminated arrangement US Patent 4,892,778 (January 9).
14. Tozuka Y., Ito A., Seki H., Oguchi T., and Yamamoto K. Characterization and quantitation of clarithromycin polymorphs by powder X-ray diffractometry and solid-state NMR spectroscopy. Chem. Pharm. Bull. 50 8 (2002) 1128-1130
15. Yam N., Shivanand P., Kimbel R., Shanbhag A., and Deng R. Characterization of a topiramate/poloxamer interaction for the development of a controlled released products". American Association of Pharmaceutical Scientists 2005 Annual Meeting. Nashville, TN, November 6-10 (2005)